INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 422m ago
HOUSE PTR22m ago
SEC 13F22m ago
ROBINHOOD CHAIN22m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Rosett Max sold IMNM

Chief Financial Officer · Immunome Inc. · Common Stock

Side
SELL
Value
$30K
Shares
1,344
Price
$22.48
Executed
Apr 2, 2026
Disclosed
Apr 3, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Apr 2 executedApr 3, 2026 disclosed

IMNM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
10/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $30K reported value · 2.4% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · IMNM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    0
    HJ
    Higgins JackChief Scientific Officer
    IMNMImmunome Inc.
    Option exercise · 10b5-1 plan
    		M—
    18.0K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    3
    HJ
    Higgins JackChief Scientific Officer
    IMNMImmunome Inc.
    Option exercise · 10b5-1 plan
    		M$24K
    18.0K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    11
    HJ
    Higgins JackChief Scientific Officer
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$334K
    13.2K sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    2
    HJ
    Higgins JackChief Scientific Officer
    IMNMImmunome Inc.
    Gift · 10b5-1 plan
    		G—
    8,800 sh
    		Sep 11, 2026Sep 15, 2026
    traded Sep 11, 2026
    		+4dSEC FORM 4

    Evidence

    8
    BI
    Barchas IsaacDirector
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$301K
    11.0K sh
    		Aug 12, 2026Aug 12, 2026
    traded Aug 12, 2026
    		+0dSEC FORM 4

    Evidence

    19
    BI
    Barchas IsaacDirector
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.63M
    62.3K sh
    		Aug 11, 2026Aug 12, 2026
    traded Aug 11, 2026
    		+1dSEC FORM 4

    Evidence

    8
    BI
    Barchas IsaacDirector
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$264K
    10.1K sh
    		Aug 10, 2026Aug 12, 2026
    traded Aug 10, 2026
    		+2dSEC FORM 4

    Evidence

    11
    BI
    Barchas IsaacDirector
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$397K
    15.2K sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    11
    BI
    Barchas IsaacDirector
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$543K
    20.8K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    26
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$499K
    22.7K sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    16
    BI
    Barchas IsaacDirector
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$409K
    16.9K sh
    		Jul 7, 2026Jul 7, 2026
    traded Jul 7, 2026
    		+0dSEC FORM 4

    Evidence

    19
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Option exercise · 10b5-1 plan
    		M$480K
    55.0K sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    23
    BI
    Barchas IsaacDirector
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2.00M
    83.1K sh
    		Jul 6, 2026Jul 7, 2026
    traded Jul 6, 2026
    		+1dSEC FORM 4

    Evidence

    9
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Option exercise · 10b5-1 plan
    		M—
    55.0K sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    30
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$377K
    16.1K sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    26
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$369K
    16.2K sh
    		Jul 2, 2026Jul 7, 2026
    traded Jul 2, 2026
    		+5dSEC FORM 4

    Evidence

    17
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Option exercise · 10b5-1 plan
    		M$480K
    55.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    33
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$794K
    40.6K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    29
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Open-market sale · 10b5-1 plan
    		SELL$298K
    14.4K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    3
    LR
    Lechleider RobertChief Medical Officer
    IMNMImmunome Inc.
    Option exercise · 10b5-1 plan
    		M—
    55.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001994071-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 2, 2026
    Published
    Apr 3, 2026
    Ingested by INSIDER
    Nov 5, 04:07 UTC
    Last re-read
    Nov 5, 04:07 UTC

    Extracted facts

    Filer
    Rosett Max
    Role
    Chief Financial Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Immunome Inc.
    Ticker
    IMNM
    Shares
    1,344
    Price per share
    $22.48
    Value
    $30,213
    Execution date (reported)
    Apr 2, 2026
    Owned after transaction
    54.0K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 1,344
    • Price: $22.48

    = $30,213

    What this establishes

    Rosett Max filed this Form 4 reporting a open-market sale of IMNM on Apr 2, 2026. It became public on Apr 3, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Rosett Maxcik:0001994071
    Issuer
    Immunome Inc.cik:0001472012

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.